Literature DB >> 10650859

Severe protein C deficiency and aseptic osteonecrosis of the hip joint: a case report.

C Wermes1, F Bergmann, B Reller, K W Sykora.   

Abstract

UNLABELLED: Homozygous congenital protein C deficiency is accompanied by severe thrombophilia. Thrombotic events can be reduced in number and severity by lifelong oral anticoagulation therapy. A 4-year-old boy was first diagnosed as having severe congenital homozygous protein C deficiency during the neonatal period when purpura fulminans occurred as the first manifestation of thrombosis. From this time he had been treated with phenprocoumon (INR 3.5-4.5). During an infection of the upper respiratory tract he developed signs of a new episode of purpura fulminans (INR 2.6). Additional anticoagulation therapy with LMW heparin (Clexane) and protein C concentrate was given while the oral anticoagulation therapy was continued. On the third day of this episode the boy suffered from pain of unknown origin. MRI of the abdomen and of the pelvis revealed nontraumatic osteonecrosis of the hip joint. After a few weeks of immobilisation no special treatment was necessary. One year later he was able to walk with no problem.
CONCLUSION: Aseptic osteonecrosis of the hip joint is associated with a variety of disorders including vascular thrombosis and haemorrhage. Especially young children and handicapped patients with thrombophilia and pain of unknown origin are suspected to have thrombosis in atypical regions.

Entities:  

Mesh:

Year:  1999        PMID: 10650859     DOI: 10.1007/pl00014345

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  4 in total

1.  Association between MTHFR C677T polymorphism and osteonecrosis of the femoral head: a meta-analysis.

Authors:  Xi-fu Shang; Hong Su; Wei-wei Chang; Chen-cheng Wang; Qin Han; Zhi-wei Xu
Journal:  Mol Biol Rep       Date:  2012-02-07       Impact factor: 2.316

Review 2.  Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients.

Authors:  Donald L Yee; Sarah H O'Brien; Guy Young
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

3.  Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency.

Authors:  Sabine Kroiss; Manuela Albisetti
Journal:  Biologics       Date:  2010-03-24

Review 4.  Genetic association between methylenetetrahydrofolate reductase gene polymorphism and risk of osteonecrosis of the femoral head.

Authors:  Wei Chai; Zhendong Zhang; Ming Ni; Peiliang Geng; Zijian Lian; Guoqiang Zhang; Lewis L Shi; Jiying Chen
Journal:  Biomed Res Int       Date:  2015-01-26       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.